SynBiotic SE (SBX) - Net Assets
Based on the latest financial reports, SynBiotic SE (SBX) has net assets worth €22.79 Million EUR (≈ $26.64 Million USD) as of December 2022. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€40.62 Million ≈ $47.49 Million USD) and total liabilities (€17.83 Million ≈ $20.85 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SBX goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €22.79 Million |
| % of Total Assets | 56.1% |
| Annual Growth Rate | 145.37% |
| 5-Year Change | -17.61% |
| 10-Year Change | N/A |
| Growth Volatility | 4285.23 |
SynBiotic SE - Net Assets Trend (2019–2024)
This chart illustrates how SynBiotic SE's net assets have evolved over time, based on quarterly financial data. See SynBiotic SE defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for SynBiotic SE (2019–2024)
The table below shows the annual net assets of SynBiotic SE from 2019 to 2024. For live valuation and market cap data, see SBX company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €21.01 Million ≈ $24.56 Million |
+37.06% |
| 2023-12-31 | €15.33 Million ≈ $17.92 Million |
-32.74% |
| 2022-12-31 | €22.79 Million ≈ $26.64 Million |
-37.94% |
| 2021-12-31 | €36.72 Million ≈ $42.94 Million |
+44.04% |
| 2020-12-31 | €25.50 Million ≈ $29.81 Million |
+10715.33% |
| 2019-12-31 | €235.75K ≈ $275.62K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SynBiotic SE's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5835454200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €81.23 Million | 355.27% |
| Total Equity | €22.87 Million | 100.00% |
SynBiotic SE Competitors by Market Cap
The table below lists competitors of SynBiotic SE ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Femasys Inc
NASDAQ:FEMY
|
$12.20 Million |
|
Nuchev Ltd
AU:NUC
|
$12.21 Million |
|
AIM Commercial Growth Freehold And Leasehold Real Estate Investment Trust
BK:AIMCG
|
$12.21 Million |
|
e-future.Co.Ltd
KQ:134060
|
$12.21 Million |
|
Spring Ventures Ltd
TA:SPRG
|
$12.19 Million |
|
Niobay Metals Inc
V:NBY
|
$12.18 Million |
|
American Manganese Inc
V:AMY
|
$12.18 Million |
|
Onelife Capital Advisors Limited
NSE:ONELIFECAP
|
$12.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SynBiotic SE's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 15,789,870 to 22,865,477, a change of 7,075,607 (44.8%).
- Net loss of 9,716,205 reduced equity.
- New share issuances of 368,131 increased equity.
- Other factors increased equity by 16,423,681.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-9.72 Million | -42.49% |
| Share Issuances | €368.13K | +1.61% |
| Other Changes | €16.42 Million | +71.83% |
| Total Change | €- | 44.81% |
Book Value vs Market Value Analysis
This analysis compares SynBiotic SE's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.41x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.44x to 0.41x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | €0.94 | €1.36 | x |
| 2020-12-31 | €9.67 | €1.36 | x |
| 2021-12-31 | €9.53 | €1.36 | x |
| 2022-12-31 | €5.00 | €1.36 | x |
| 2023-12-31 | €3.15 | €1.36 | x |
| 2024-12-31 | €3.35 | €1.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SynBiotic SE utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -42.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -67.92%
- • Asset Turnover: 0.31x
- • Equity Multiplier: 2.00x
- Recent ROE (-42.49%) is above the historical average (-43.70%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -5.70% | 0.00% | 0.00x | 1.01x | €-37.00K |
| 2020 | -2.47% | -567.57% | 0.00x | 1.37x | €-3.18 Million |
| 2021 | -36.36% | -140.39% | 0.15x | 1.73x | €-16.22 Million |
| 2022 | -107.83% | -298.35% | 0.20x | 1.80x | €-26.62 Million |
| 2023 | -67.33% | -275.31% | 0.11x | 2.21x | €-12.21 Million |
| 2024 | -42.49% | -67.92% | 0.31x | 2.00x | €-12.00 Million |
Industry Comparison
This section compares SynBiotic SE's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $5,659,440,547
- Average return on equity (ROE) among peers: -44.43%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SynBiotic SE (SBX) | €22.79 Million | -5.70% | 0.78x | $12.19 Million |
| SHANG.FOS.PHARM.GR.H YC 1 (08HH) | $48.38 Billion | 9.77% | 0.93x | $1.13 Billion |
| PEPTONIC MEDICAL (28L) | $48.55 Million | -123.64% | 0.45x | $4.14 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $7.85 Billion | 28.40% | 0.37x | $692.11 Million |
| WEST ISLAND BRANDS INC. (39N0) | $3.27 Million | -157.21% | 0.88x | $1.34 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $2.69 Million | -197.11% | 3.73x | $97.35K |
| CERENO SCIENTIFIC AB B (4A1) | $170.06 Million | -9.56% | 0.06x | $157.72 Million |
| MAPLE LEAF GREEN WORLD (4HV0) | $-8.83 Million | 0.00% | 0.00x | $504.30K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-815.79K | 0.00% | 0.00x | $134.78K |
| RED LIGHT HOLLAND CORP. (4YX) | $26.34 Million | -20.49% | 0.14x | $7.31 Million |
| EQL PHARMA AB (7JK) | $123.63 Million | 25.52% | 0.92x | $73.36 Million |
About SynBiotic SE
SynBiotic SE engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety. It also offers hemp, cannabinoids, dietary supplements, and cosmetic products; medical cannabis products; and cannabis products for recreational use under the Hempamed, Princess Stardust, The Hempany, and Hempamed Rx brand names. T… Read more